B
Beam Therapeutics D
D
BEAM
24.540
USD
0.96
(4.07%)
Market Open
Volume
20,652
EPS
-5
Div Yield
-
P/E
-16
Market Cap
2,032,050,087
Novo Nordisk Surges in Profit and Sales
6 months ago
Stocks news More
Title: Beam Therapeutics
Sector: Healthcare
Industry: Biotechnology
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making adouble-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.